



Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

June 1, 2026

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Executive Officer, CFO
(Telephone Number: +81-76-421-5665)

Notice Regarding the Completion of Cancellation of Treasury Shares
(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)

Daito Pharmaceutical Co., Ltd. (the “Company”) hereby announces that the Company completed the cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act on May 29, 2026, as resolved by the Board of Directors at a meeting on May 13, 2026.

- | | |
|------------------------------------|---|
| 1. Class of shares canceled | Common stock |
| 2. Total number of shares canceled | 1,242,000 shares
(4.1% of total shares issued before cancellation) |
| 3. Cancellation date | May 29, 2026 |

(Reference)

Total number of shares issued after cancellation 28,854,880 shares
Number of treasury shares after cancellation 16,718shares*1

*1 The number of treasury shares following the above cancellation does not include the 94,340 shares of the Company held in trust under the stock delivery trust for Board Directors (excluding Board Directors who are Audit and Supervisory Committee Members and Outside Directors).

End